Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Linda Cicciarelli"'
Autor:
Kirsten Allan, Linda Cicciarelli, Catherine Beard, Geoffrey J. Lindeman, G Bruce Mann, Paul James, Laura E. Forrest
Germline genetic testing is an increasingly important component of treatment decision-making for clinicians and patients with breast cancer. To address increased demand and expedite access to genetic testing for these patients, the Parkville Familial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8ef508846e14fef7b941004053795c8
https://doi.org/10.21203/rs.3.rs-2483180/v1
https://doi.org/10.21203/rs.3.rs-2483180/v1
Publikováno v:
Eur J Hum Genet
The demand for genetic testing of hereditary breast cancer genes such as BRCA1 and BRCA2 has continued to increase with the lowering costs of testing, raised awareness in the general public, and implications for breast cancer treatment when a patient
Autor:
Christobel Saunders, Yoland Antill, Kaaren J. Watts, Veronica F. Quinn, Katherine M. Tucker, Marion Harris, Bettina Meiser, Kristine Barlow-Stewart, Judy Kirk, Gillian Mitchell, Michelle Peate, Belinda Rahman, Elizabeth Geelhoed, Michael T. Bowen, Linda Cicciarelli, Karen Crowe, Michael Field, Margaret Gleeson
Publikováno v:
Genetics in Medicine. 19:448-456
Increasingly, women newly diagnosed with breast cancer are being offered treatment-focused genetic testing (TFGT). As the demand for TFGT increases, streamlined methods of genetic education are needed. In this noninferiority trial, women aged
Autor:
John L. Hopper, Melissa C. Southey, Paul A. James, Gillian S. Dite, David E. Goldgar, Carmel Apicella, Linda Cicciarelli, Daniel J. Park, Saundra S. Buys, Elena Provenzano, Fabrice Odefrey, James G. Dowty, G.G. Giles, S Sawyer, Mary Beth Terry, Alison H. Trainer, Tu Nguyen-Dumont, Anna Marie Mulligan, Zhi Ling Teo, Esther M. John, Mary B. Daly, Geoffrey J. Lindeman, Irene L. Andrulis, Ingrid Winship, Gillian Mitchell, Kylie Shackleton, Gord Glendon
Publikováno v:
British Journal of Cancer
Background: Population-based studies of breast cancer have estimated that at least some PALB2 mutations are associated with high breast cancer risk. For women carrying PALB2 mutations, knowing their carrier status could be useful in directing them to
Autor:
Kylie Shackleton, Paul A. James, Alison H. Trainer, Linda Cicciarelli, Geoffrey J. Lindeman, S Sawyer, Melissa C. Southey, Gillian Mitchell, Zhi Ling Teo
Publikováno v:
Familial Cancer. 12:587-595
The familial aggregation of breast cancer has been well-described with approximately 25 % of breast cancers attributable to inherited mutations in currently known breast cancer susceptibility genes. PALB2 c.3113G>A (p.Trp1038*) is a protein-truncatin
Autor:
Lewis A, Pandey D, Driessen R, Linda Cicciarelli, M. Young, S Sawyer, Gillian Mitchell, Lovett Cm
Publikováno v:
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 10, Iss Suppl 2, p A49 (2012)
Hereditary Cancer in Clinical Practice, Vol 10, Iss Suppl 2, p A49 (2012)
Background The growth of a personalised approach to cancer treatment including surgical risk management strategies and Parp Inhibitor trials for BRCA1/2 mutation carriers has lead to the Peter MacCallum Familial Cancer Centre experiencing a rapidly i